0
Biogénesis Bagó, the biotechnology company specialized in the development, production and commercialization of solutions for animal health, has obtained EuFMD prequalification for its foot-and-mouth disease vaccine BIOAFTOGEN®, becoming the first company in the world to receive this certification granted by the European initiative that advocates for the control of foot-and-mouth disease in the continent.
The European Commission for the Control of Foot and Mouth Disease is constantly working together with countries in the region to implement various policies to control and prevent the threat of FMD and other transboundary diseases and promote the progressive control of this disease globally, all within the framework of the Global FMD Control Strategy of FAO and the World Organization for Animal Health (WOAH). Aligned with this strategy, in 2021 the organization established a vaccine prequalification system (PQv) against transboundary diseases (FAST) that seeks to ensure the supply of quality FMD vaccines on behalf of member states.
The prequalification obtained by Biogénesis Bagó is a new achievement in the company’s long history in the prevention and control of animal diseases, given that for more than 70 years has been committed to the research and development of solutions for the fight against foot and mouth disease, among others. This track record has positioned BIOAFTOGEN® as a world-class vaccine that meets the quality standards established by the most demanding health organizations in the world.
This achievement enhances the company´s position as a global leader in FMD prevention and reinforces its commitment to the collaboration with leading technical and scientific organizations, contributing to food safety and animal health status worldwide.
November 15, 2023 - Biogénesis Bagó
